|
[1]Elsharkawy AM, Oakley F, Mann DA.The role and regulation of he-patic stellate cell apoptosis in reversal of liver fibrosis[J].Apoptosis.2005, 10 (5) :927-39.
|
|
[2]Liu HL, Li XH, Wang DY, et al.Matrix metalloproteinase-2and tissue inhibitor of metalloproteinase-1expression in fibrotic rat liver[J].World J Gastroenterology, 2000, 6:881-884.
|
|
[3]Curran S, Murray GI.Matrix metalloproteinase:molecular aspects of their roles in tumor invasion and metastasis[J].Eur J Cancer, 2000, 36:1621-1630.
|
|
[4]Waas ET, Lomme RM, DeGroot J, et al.Tissue levels of active ma-trix metalloproteinase-2and9in colorectal cancer[J].Br J Cancer, 2002, 86:1876-1883.
|
|
[5]Kleiner DE, Stetler-Stevenson WG.Matrix metalloproteinases and metastasis[J].Cancer Chemother Pharmacol, 1999, 43 (Suppl) :S42-51.
|
|
[6]Ji F, Wang WL, Yang ZL, et al.Study on the expression of matrix metallo proteinase-2mRNA in human gastric cancer[J].World J Gastroenterol, 1999, 5:455-457.
|
|
[7] 蒋泽生, 高毅.基质金属蛋白酶的生物学特性及其在肿瘤浸润转移中的作用[J].世界华人消化杂志, 2000, 8:1403-1404.
|
|
[8]Ellenrieder V, Alber B, Lacher U, et al.Role of MT-MMPs and MMP-2in pancreatic cancer progression[J].Int J Cancer, 2000, 85:14-20.
|
|
[9]Huhtala P, ChowLT, Tryggvason K.Structure of the human typeⅣcollagenase gene[J].J Biol Chem, 1990, 265:1107-1108.
|
|
[10]孙晓敏, 董卫国, 余保平, 等.恶性腹水基质金属蛋白酶活性分析[J].世界华人消化杂志, 2004, 12 (2) :376-378.
|
|
[11]韩明子, 范玉晶, 王双双.基质金属蛋白酶-2, -9及铁蛋白对鉴别良恶性腹水的意义[J].世界华人消化杂志, 2005, 13 (7) :927-928.
|
|
[12] 林红, 罗辉.血管内皮生长因子与恶性体腔积液[J].中华医学全科杂志, 2003, 11 (2) :41-44.
|
|
[13]Chandra A, Angle N.Vascular endothelial growth factor stimulates a novel calcium-signaling pathway in vascular smooth muscle cells[J].Surgery, 2005, 138 (4) :780-7.
|
|
[14]Nasciment I, Schaer R, Lemaire D, et al.Vascular endothelial growth factor (VEGF) levels as a tool to discriminate between malig-nant and nonmalignant ascites[J].APMIS, 2004, 112 (9) :585-7.
|
|
[15]孙晓敏, 董卫国, 高礼层.血管内皮生长因子在恶性腹水诊断及形成中的作用[J].中国综合临床, 2004, 20 (4) :334-336.
|
|
[16]Nagy JA, Masse EM, Herzberg KT, et al.Pathogenesis of ascites tumor growth:vascular perm eabifity factor, vascular hyperperme-ability, and ascites fluid accumulation[J].Cancer Res, 1995, 55 (2) :360-36.
|
|
[17]Luo JC, Toyoda M, Shibuya M.Differential inhibition of fluid ac-cumulationan dtumor growt hintwo mouse ascites tumors by an antiva-seular endothelial growth factor/permeability factor neutralizing anti-body[J].Cancer Res, 1998, 58 (12) :2594-2600.
|
|
[18]Mesiano S, Ferrara N, Jafe RB.Role of vascular endothelial growth factor in ovarian cancer:inhibition of ascites form ation by immunon-eutralization[J].American Journal of Pathology, 1998, 153 (4) :1249-1256.
|
|
[19]Tandle A, Libutti SK.Antiangiogenic therapy:targeting vascular endothelial growth factor and its receptors[J].Clin Adv Hematol On-col, 2003, 1 (1) :41-8.
|
|
[20]Wakelee HA, Schiller JH.Targeting angiogenesis with vascular en-dothelial growth factor receptor small-molecule inhibitors:novel a-gents with potential in lung cancer[J].Clin Lung Cancer, 2005, 7S1:S31-8.
|
|
[21]Roudebush WE, Massey JB, Elsner CW, et al.The significance of platelet-activating factor and fertility in the male primate:a review[J].J Med Primatol, 2005, 34 (1) :20-4.
|
|
[22]Yoo J, Sehhmdoree D, Neugardten J.Thromboxane medicates ther-enal hemodynamic effect of plateleth activating factor[J].J Pharma-col Exp Ther, 1990, 253 (3) :743-748.
|
|
[23]Marrache AM, Gobeil F, Zhu T, et al.Intracellular signaling of lipid mediators via cognate nuclear G protein-coupled receptors[J].Endothelium, 2005, 12 (1-2) :63-72.
|
|
[24] 曾宁心, 王家马龙.肝硬变患者血浆血小板活化因子检测及其内毒素血症的关系[J].中华医学杂志, 1992, 72 (3) :141-143.
|
|
[25]Guarner F, Wallace JL, MacNaughton WK, et al.Endotoxin-in-duced ascites formation in the rat:partial mediation by platelet-ac-tivating factor[J].Hepatology, 1989, 10 (5) :788-94.
|
|
[26]Fecchio D, Russo M, Sirois P, et al.Inhibition of Ehrlich ascites tumor in vivo by PAF-antagonists[J].Int J Immunopharmacol, 1990, 12 (1) :57-65.
|
PDF下载 ( 114 KB)
本文二维码
下载:
